<!DOCTYPE html>
<html lang="en">
	<head>
		<!--Meta tags-->
		<meta charset="UTF-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1.0" />
		<!--Open Graph Tags-->
		<meta property="og:site_name" content="TBFighters" />
		<meta property="og:url" content="https://tbfighters.org" />
		<meta property="og:type" content="website" />
		<meta property="theme-color" content="#D7211E" />
		<!-- Style Tags -->
		<link rel="stylesheet" href="style.css" />
		<link rel="stylesheet" href="libs/toastify/toastify.css">
		<link rel="apple-touch-icon" sizes="180x180" href="img/favicon/apple-touch-icon.png">
		<link rel="icon" type="image/png" sizes="32x32" href="img/favicon/favicon-32x32.png">
		<link rel="icon" type="image/png" sizes="16x16" href="img/favicon/favicon-16x16.png">
		<link rel="manifest" href="img/favicon/site.webmanifest">
		<link rel="icon" type="image/x-icon" href="img/favicon/favicon.ico">
		<script src="menu.js" defer></script>
		<script src="libs/toastify/toastify.js"></script>
		<!-- Variable Tags -->
		<meta name="robots" content="index, follow" />
		<meta property="og:title" content="News and Timeline | TBFighters" />
		<meta property="og:image" content="https://tbfighters.org/img/og-image.jpg" />
		<meta property="og:description" content="Fighting for accessible tuberculosis testing and treatment to save over a million lives a year. Take action with us now." />
		<meta name="description" content="Fighting for accessible tuberculosis testing and treatment to save over a million lives a year. Take action with us now." />

		<link rel="stylesheet" href="timeline.css" />
		<title>News and Timeline | TBFighters</title>
	</head>
	<body class="timeline">
		<header id="site-head"><a href="#main" class="skip">Skip to main content</a>
			<div class="wrapper-head">
		
				<div class="page-title">
					<a href="index.html"><img src="img/simplified-hourglass.png" alt=""><span
							class="black-highlight">TB</span>FIGHTERS</a>
				</div>
				<a id="hamburger-button" href="#" title="menu"></a>
				<nav class="site-menu">
					<ul class="active">
						<li class="dropdown lined" id="nav-about">
							<div>
								<div class="mobile"></div>
								<a href="about.html" class="title">About Us</a><button
									aria-label="Open menu About us" class="dropdown-button"><img
										src="img/chevron-white.svg"
										alt="dropdown arrow"></button>
							</div>
							<ul class="dropdown-content">
								<li><a href="book-club" class="title">TBReaders Bookclub</a>
								</li>
								<li><a href="timeline.html" class="title">News & Timeline</a>
								</li>
							</ul>
						</li>
						<li class="non-dropdown lined" id="nav-learn-more"><a class="title"
								href="resources.html">About TB</a></li>
						<li class="dropdown lined" id="nav-take-action">
							<div>
								<div class="mobile"></div>
								<a class="title" href="action.html">Take Action</a><button
									aria-label="Open menu Take Action" class="dropdown-button"><img
										src="img/chevron-white.svg"
										alt="dropdown arrow"></button>
							</div>
							<ul class="dropdown-content">
								<li><a href="danaher/" class="title">Affordable Testing</a></li>
								<li><a href="funding-cuts/" class="title">Funding Cuts</a></li>
								<li><a href="hill-day/" class="title">US Hill Day</a></li>
								<li><a href="templates/" class="title">Templates</a></li>
							</ul>
						</li>
						<li class="non-dropdown socials" id="nav-socials">
							<p class="smaller socials-wrapper">
								<a href="https://newsletter.tbfighters.org/subscribe" target="_blank"><img
										src="img/socials/newsletter.svg"
										aria-label="Newsletter" class="social-icon"><img
										src="img/socials/newsletter-hover.svg"
										class="social-icon-hover"></a>
								<a href="https://bsky.app/profile/tbfighters.org" target="_blank"><img
										src="img/socials/bsky-nav.svg"
										aria-label="Blue Sky" class="social-icon"><img
										src="img/socials/bsky-nav-hover.svg"
										class="social-icon-hover"></a>
								<a href="https://www.instagram.com/tbfighters" target="_blank"><img
										src="img/socials/insta-nav.svg"
										aria-label="Instagram" class="social-icon"><img
										src="img/socials/insta-nav-hover.svg"
										class="social-icon-hover"></a>
								<a href="https://www.youtube.com/@TB_Fighters" target="_blank"><img
										src="img/socials/youtube-nav.svg"
										aria-label="Youtube" class="social-icon"><img
										src="img/socials/youtube-nav-hover.svg"
										class="social-icon-hover"></a>
							</p>
						</li>
					</ul>
				</nav>
		
			</div>
		</header>
		<main id="main">
			<section class="container container-compact title">
				<div class="wrapper-full">
					<h1 class="break-anywhere">TBFighters Milestones and News</h1>
					<p>
						This page covers actions, milestones, and announcements related to TBFighter actions (related to Johnson &amp; Johnson and Danaher/Cepheid) in reverse chronological order, starting with the most recent. This is not meant to be a complete timeline of global health efforts to fight tuberculosis&mdash;you can find more information beyond this timeline from <a href="https://msfaccess.org/time-for-5" target="_blank">MSF's page on the Time for $5 campaign</a>, the community-developed <a href="https://tuberculosis.miraheze.org/" target="_blank">Tuberculosis Wiki</a>, and our <a href="resources.html">resources page (including glossary)</a>.
					</p>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="march-22-2024">
				<div class="wrapper-full">
					<div class="date">
						<h2>March 22, 2024</h2>
					</div>
					<div class="item">
						<p>
							MSF Access <a href="https://timefor5.msfaccess.org/" target="_blank">releases a petition</a> calling on Danaher to lower all GeneXpert test cartridges to $5 in low- and middle-income countries. The following Tuesday, John Green <a href="https://www.youtube.com/watch?v=uizFXzSTeVs" target="_blank">releases a video</a> supporting the petition and discussing his intention to engage in shareholder activism. TBFighters sign and amplify the petition, and continue to call, email, and post on social media, pushing for all test prices to be lowered to $5, not just MTB/RIF tests at $7.97.
						</p>
						<p>
							<a class="button" href="https://timefor5.msfaccess.org/" target="_blank">Sign the petition</a>
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="september-29-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>Sept 29, 2023</h2>
					</div>
					<div class="item">
						<p>
							<a href="johnson-secondary-patents.html">Johnson &amp; Johnson announces that they will not enforce secondary patents</a> for bedaquiline in 134 low- and middle-income countries. This builds upon their previous agreement with the Stop TB Partnership (see July 13), which allowed for generic bedaquiline in 44 countries, and <strong>fulfills the initial ask of the #PatientsOverPatents campaign</strong>.
						</p>
						<p>
							<a class="button" href="johnson-secondary-patents.html">Read announcement</a>
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="september-19-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>Sept 19, 2023</h2>
					</div>
					<div class="item">
						<p>
							<a href="danaher-rif.html">Danaher announces that they will reduce the cost of the Xpert MTB/RIF cartridge</a> to US$7.97, which they claim is the cost to produce, and agree to an external verification of the price on an annual basis. XDR cartridges are not included in this announcement. The Time for $5 Coalition and TBFighters continue to push for lower prices for XDR tests and tests for other diseases.
						</p>
						<p>
							XDR cartridges and tests for other diseases are the <a href="action.html">current target of the TBFighters campaign</a>.
						</p>
						<p>
							<a class="button" href="danaher-rif.html">Read announcement</a>
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="september-12-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>Sept 12, 2023</h2>
					</div>
					<div class="item">
						<p>
							<strong>The first phase of the TBFighters campaign</strong> to reduce GeneXpert TB test cartridge prices goes live, starting with a <a href="https://www.youtube.com/watch?v=tSC06P9A5W4" target="_blank">video from John Green</a>. People are encouraged to send emails, letters, phone calls, and post on social media about the Time for $5 campaign.
						</p>
						<p>
							The next day Danaher shuts down their main phone lines, and both #PeopleOverProfits and #TimeFor5 trend on social media multiple times throughout the next week.
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="august-30-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>August 30, 2023</h2>
					</div>
					<div class="item">
						<p>
							<strong>John Green introduces Nerdfighteria to GeneXpert catridges</strong> and the MSF "Time for $5" campaign in the first of a series of livestreams.
						</p>
						<p>
							Over the next 13 days, Nerdfighteria groups get together to find an outstanding amount of information on Danaher, Cepheid, and the products they produce, and organize a cohesive plan to make the case for lower prices of Xpert MTB/RIF and MTB/XDR tests.
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="july-13-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>July 13, 2023</h2>
					</div>
					<div class="item">
						<p>
							The Stop TB Partnership and Global Drug Facility <a href="https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline" target="_blank">publicly announce that Johnson &amp; Johnson has granted them a license to supply generic versions of bedaquiline in some low- and middle-income countries</a>. The details of this agreement, including countries covered, are not released until later.
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="july-12-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>July 12, 2023</h2>
					</div>
					<div class="item">
						<p>
							<a href="https://twitter.com/JNJNews/status/1679168314986094592" target="_blank">Johnson &amp; Johnson responds publicly to the #PeopleOverProfits campaign</a> with a statement on Twitter that reads, in part: "It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB." Their statement touts J&amp;J's work in developing and donating TB-related treatments, and admits that the lack of testing is the highest barrier to treatment.
						</p>
						<p>
							TBFighters respond, in part, with the small impact that Johnson &amp; Johnson's 600,000 courses of donated bedaquiline over 10 years has had on the 32 million people who died from TB during that time frame. "It is false to suggest—as some recently have—" becomes a meme and rallying cry for TBFighters.
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact container-timeline" id="july-11-2023">
				<div class="wrapper-full">
					<div class="date">
						<h2>July 11, 2023</h2>
					</div>
					<div class="item">
						<p>
							<a href="https://www.youtube.com/watch?v=tMhgw5SW0h4" target="_blank">John Green announces an effort to ask Johnson &amp; Johnson to allow their patents on bedaquiline to lapse</a> without enforcing secondary patents, at least in countries that have a high tuberculosis burden or are considered low- to middle-income.
						</p>
						<p>
							TBFighters flood Johnson &amp; Johnson's phone lines, emails, and social media, telling them to adhere to their credo, which partially reads: "Our first responsibility is to the patients." This also marks the adoption of the #PeopleOverProfits hashtag and message by TBFighters and other groups involved in the Time For $5 campaign. The hashtag trends on several platforms over the next few days.
						</p>
					</div>
				</div>
			</section>
			<section class="container container-compact">
				<div class="wrapper-full">
					<p>
						<a href="action.html">Take action now and add to this timeline!</a>
					</p>
					
				</div>
			</section>
		</main>
		<footer class="site-foot">
				<p class="socials-wrapper-centered socials-wrapper">
					<a href="https://bsky.app/profile/tbfighters.org" target="_blank"><img
						src="img/socials/bsky.svg" aria-label="Blue Sky" class="social-icon"><img
						src="img/socials/bsky-hover.svg" class="social-icon-hover"></a>
					<a href="https://x.com/tbfighters" target="_blank">
						<img src="img/socials/twitter.svg" aria-label="Twitter" class="social-icon">
						<img src="img/socials/twitter-hover.svg" class="social-icon-hover"></a>
					<a href="https://www.instagram.com/tbfighters" target="_blank">
						<img src="img/socials/insta.svg" aria-label="Instagram" class="social-icon">
						<img src="img/socials/insta-hover.svg" class="social-icon-hover"></a>
					<a href="https://www.youtube.com/@TB_Fighters" target="_blank"><img
						src="img/socials/youtube.svg" aria-label="Youtube" class="social-icon"><img
						src="img/socials/youtube-hover.svg" class="social-icon-hover"></a>
					<a href="https://www.facebook.com/profile.php?id=61555332203505" target="_blank"><img
						src="img/socials/facebook.svg" aria-label="Facebook" class="social-icon"><img
						src="img/socials/facebook-hover.svg" class="social-icon-hover"></a>
				</p>
				<hr style="width: 10%; margin: 0 auto; margin-bottom: 4px;">
				<p>
					&copy; The TBFighters Project | <a href="privacy.html" class="footer-link">Privacy Policy</a>
				</p>
				<p class="too-small">
					
					We lead by following and we act with compassion. Get in touch: contact at tbfighters dot org
				</p>
			</footer>
</body>
</html>
